120 related articles for article (PubMed ID: 38548131)
21. Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score.
Bargellini I; Scalise P; Boni G; Traino CA; Bozzi E; Lorenzoni G; Crocetti L; Cioni R
J Vasc Interv Radiol; 2020 Dec; 31(12):2028-2032. PubMed ID: 33121865
[TBL] [Abstract][Full Text] [Related]
22. A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC.
Nam JY; Lee YB; Lee JH; Yu SJ; Kim HC; Chung JW; Yoon JH; Kim YJ
Dig Dis Sci; 2022 Jan; 67(1):329-336. PubMed ID: 33538921
[TBL] [Abstract][Full Text] [Related]
23. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
24. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma.
Iñarrairaegui M; Martinez-Cuesta A; Rodríguez M; Bilbao JI; Arbizu J; Benito A; Alegre F; D'Avola D; Herrero JI; Quiroga J; Prieto J; Sangro B
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1441-8. PubMed ID: 20056355
[TBL] [Abstract][Full Text] [Related]
25. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
[No Abstract] [Full Text] [Related]
26. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
[TBL] [Abstract][Full Text] [Related]
28. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
[TBL] [Abstract][Full Text] [Related]
30. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation.
Gordon AC; Gupta AN; Gabr A; Thornburg BG; Kulik LM; Ganger DR; Maddur H; Flamm SL; Boike JR; Moore CM; Borja-Cacho D; Christopher DA; Katariya NN; Ladner DP; Caicedo-Ramirez JC; Riaz A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2021 Feb; 32(2):211-219. PubMed ID: 33349507
[TBL] [Abstract][Full Text] [Related]
32. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
33. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software.
Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB
J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416
[TBL] [Abstract][Full Text] [Related]
34. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
[TBL] [Abstract][Full Text] [Related]
35. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
[TBL] [Abstract][Full Text] [Related]
36. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
Rhee H; Cho ES; Nahm JH; Jang M; Chung YE; Baek SE; Lee S; Kim MJ; Park MS; Han DH; Choi JY; Park YN
J Hepatol; 2021 Jan; 74(1):109-121. PubMed ID: 32818570
[TBL] [Abstract][Full Text] [Related]
37. Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.
Dhingra S; Schwartz M; Kim E; Mabel Ko H; Ward SC; Fiel MI; Thung SN
Semin Liver Dis; 2014 Nov; 34(4):465-8. PubMed ID: 25369308
[TBL] [Abstract][Full Text] [Related]
38. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
39. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB
J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981
[TBL] [Abstract][Full Text] [Related]
40. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
